Media coverage about Lexicon Pharmaceuticals (NASDAQ:LXRX) has trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Lexicon Pharmaceuticals earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 46.0922936856189 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the media headlines that may have effected Accern’s rankings:
- FY2019 Earnings Estimate for Lexicon Pharmaceuticals, Inc. Issued By Wedbush (LXRX) (americanbankingnews.com)
- Lexicon Pharmaceuticals, Inc. :LXRX-US: Earnings Analysis: Q2, 2017 By the Numbers : October 4, 2017 (finance.yahoo.com)
- ETFs with exposure to Lexicon Pharmaceuticals, Inc. : October 5, 2017 (finance.yahoo.com)
- Lexicon Pharmaceuticals, Inc. (LXRX) Given Outperform Rating at Wedbush (americanbankingnews.com)
A number of analysts have commented on the company. Wedbush reissued an “outperform” rating on shares of Lexicon Pharmaceuticals in a report on Thursday, October 5th. Needham & Company LLC reissued a “buy” rating and issued a $21.00 target price on shares of Lexicon Pharmaceuticals in a report on Sunday, September 17th. BidaskClub lowered Lexicon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Thursday, August 10th. Cowen and Company reissued a “hold” rating on shares of Lexicon Pharmaceuticals in a report on Tuesday, August 1st. Finally, Zacks Investment Research raised Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, July 18th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the company. Lexicon Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $28.75.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.12. The company had revenue of $12.00 million for the quarter, compared to the consensus estimate of $18.34 million. Lexicon Pharmaceuticals had a negative return on equity of 94.87% and a negative net margin of 170.63%. The firm’s revenue for the quarter was down 40.3% compared to the same quarter last year. During the same period last year, the firm earned ($0.37) EPS. On average, equities analysts anticipate that Lexicon Pharmaceuticals will post ($1.47) EPS for the current year.
In related news, insider Lonnel Coats purchased 30,000 shares of the business’s stock in a transaction on Friday, September 15th. The shares were bought at an average cost of $12.54 per share, with a total value of $376,200.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. 5.77% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact Lexicon Pharmaceuticals (LXRX) Share Price” was originally posted by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another publication, it was stolen and republished in violation of U.S. and international trademark & copyright laws. The correct version of this report can be read at https://www.com-unik.info/2017/10/11/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-lexicon-pharmaceuticals-lxrx-share-price.html.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.
What are top analysts saying about Lexicon Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Lexicon Pharmaceuticals Inc. and related companies.